Estimation of the Percentage of US Patients With Cancer Who Benefit From Genome-Driven Oncology

IMPORTANCE: To date, the benefit of genome-driven cancer therapy has not been quantified. OBJECTIVE: We sought to estimate the annual percentage of patients in the United States with advanced or metastatic cancer who could be eligible for and benefit from US Food and Drug Administration (FDA)-approv...

Full description

Saved in:
Bibliographic Details
Published in:JAMA Oncol
Main Authors: Marquart, John, Chen, Emerson Y., Prasad, Vinay
Format: Artigo
Language:Inglês
Published: American Medical Association 2018
Subjects:
Original Investigation
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6143048/
https://ncbi.nlm.nih.gov/pubmed/29710180
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2018.1660
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items